Eli Lilly scores positive phase III results with new eczema treatment
From a total of five phase III trials involving drug candidate lebrikizumab treating atopic dermatitis, three studies have produced positive results.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN
While Sanofil continues to triumph with eczema drug Dupixent, with Leo Pharma also working to launch its medicament, Adtralza, targeting the skin disease, both in the EU and US, Eli Lilly now moves closer to the finish line with its treatment candidate.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA gives Saniona candidate priority status
For subscribers
.jpg&w=384&q=75)
